Methionine enkephalin

Drug Profile

Methionine enkephalin

Alternative Names: INNO-105; IRT-101; IRT-102; MENK; Met-enkephalin; OGF; Opioid growth factor

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Cytocom; Hubei Qianjiang Pharmaceutical; Immune Therapeutics; Penn State College of Medicine
  • Class Antivirals; Enkephalins; Essential amino acids; Opioid peptides; Small molecules
  • Mechanism of Action Immunomodulators; Immunostimulants; Opioid growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma; HIV infections; Ovarian cancer; Pancreatic cancer
  • No development reported Solid tumours
  • Discontinued Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours in China (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Late-stage disease) in USA (IV)
  • 27 Jun 2017 Immune Therapeutics plans to complete GLP-toxicology studies by the end of fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top